DRRX שווי כולל של נכסי החברה DURECT Corp.

This price visualization of DURECT Corporation (DRRX) total assets, valued at 24.70, assists in the basic asset valuation and demonstrates the resources of the developer of epigenetic treatments for severe liver damage, protected by patents and unique developments regarding larsucetid. The company is currently conducting clinical trials for larsucetid, creating the world's first therapy for acute alcoholic hepatitis. Business development relies on joint research with pharmaceutical behemoths in the field of genetics.

To identify stability drivers for DURECT Corporation (DRRX), investors must evaluate the aggregate resource potential, which in this forecast of assets and resources is calculated inversely via return on assets (ROA). The trend of this metric reflects the company's ability to accumulate the capital necessary to complete clinical trials and deploy the production of drugs for the therapy of acute liver diseases.